Skip to main content
SpringerLink
Log in

Taxane in der Chemotherapie des hormonrefraktären Prostatakarzinoms

  • Zum Thema: Prostatakarzinom
  • Published:
Der Urologe, Ausgabe A Aims and scope Submit manuscript

Zusammenfassung

Das Prostatakarzinom stellt eine der häufigsten malignen Erkrankungen beim Mann dar. Die Therapie der Wahl des metastasierten Prostatakarzinoms besteht in der Androgenablation. Dabei handelt es sich um eine palliative Therapie, bei der die Dauer des Ansprechens begrenzt ist. Im hormonrefraktären Stadium des Prostatakarzinoms waren die Ansprechraten der verfügbaren Chemotherapien bis vor etwa 10 Jahren nur unbefriedigend. Durch die steigende Lebenserwartung und die frühere Diagnose und Therapie des Prostatakarzinoms befinden sich heute mehr Patienten mit einem hormonrefraktären Prostatakarzinom (HRPC) in relativ gutem Allgemeinzustand.

Mit den Taxanen stehen heute wesentlich erfolgversprechendere Substanzen für eine Chemotherapie beim HRPC zur Verfügung. Mit der modernen taxanbasierten Chemotherapie kann eine effektive Schmerzpalliation bei weitgehender Erhaltung der Lebensqualität bei 50–70% der Patienten erreicht werden. Darüber hinaus gibt es Hinweise für eine Verlängerung des Überlebens durch eine Chemotherapie mit Taxanen. Der Beweis dafür steht jedoch noch aus. Der aktuelle Stand klinischer Studien zur taxanbasierten Mono- und Kombinationstherapie sowie neuer Therapieansätze in Kombination mit Docetaxel wird im vorliegenden Übersichtsartikel dargestellt.

Abstract

Prostate cancer represents one of the most prevalent malignancies in men. Standard therapy of metastatic prostate cancer consists of androgen deprivation, which is a palliative therapy yielding a clinical response of limited duration. In hormone-refractory prostate cancer (HRPC), response to chemotherapy with regimens available until about ten years ago has been disappointing. Nowadays, due to increasing life expectancy and earlier diagnosis and therapy of prostate cancer, more patients with hormone-refractory disease are still in relatively good overall condition. With the taxanes, much more effective cytostatic substances for chemotherapy of HRPC are available today. Using modern taxane-based chemotherapy, effective palliation of pain can be achieved in 50–70% of patients with HRPC, while retaining an acceptable quality of life. There is also evidence for improved overall survival after taxane-based chemotherapy, although this remains to be proven by ongoing studies. This article presents an overview of current studies investigating the outcome after taxane-based chemotherapy, as well as new therapeutic approaches in combination with docetaxel.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Ascherman JA, Knowles SL, Attkiss K (2000) Docetaxel (taxotere) extravasation: a report of five cases with treatment recommendations. Ann Plast Surg 45/4: 438–441

    Google Scholar 

  2. Beer TM, Eilers KM, Garzotto M et al. (2003) Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol 21/1: 123–128

    Google Scholar 

  3. Beer TM, Pierce WC, Lowe BA, Henner WD (2001) Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann Oncol 12/9: 1273–1279

    Google Scholar 

  4. Berry W, Dakhil S, Gregurich MA, Asmar L (2001) Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol 28 (4 Suppl 15): 8–15

    Article  CAS  Google Scholar 

  5. Carroll PR, Kantoff PW, Balk SP et al. (2002) Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer. Urology 60 (3 Suppl 1): 1–6

    Article  Google Scholar 

  6. Chi KN, Murray RN, Gleave ME et al. (2003) A phase II study of oblimersen sodium (G3139) and docetaxel (D) in patients with metastatic hormone-refractory prostate cancer (HRPC). Proc ASCO 22: 1580

    Google Scholar 

  7. Collette L, Fossa SD, Oosterhof GON (2003) Baseline quality of life measured with the EORTC QLQ-C30 helps to select a subset of ‚good prognosis‘ metastatic hormone refractory prostate cancer patients. Eur J Cancer 37 (Suppl 6): 218

    Article  Google Scholar 

  8. Dahut WL, Arlen PM, Gulley J et al. (2002) A randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. Proc Am Soc Clin Oncol 21: 183a

    Google Scholar 

  9. Esmaeli B, Hortobagyi GN, Esteva FJ, et al. (2002) Canalicular stenosis secondary to weekly versus every-3-weeks docetaxel in patients with metastatic breast cancer. Ophtalmology 109: 1188–1191

    Article  Google Scholar 

  10. Fitzpatrick FA, Wheeler R (2003) The immunopharmacology of paclitaxel (Taxol(r)), docetaxel (Taxotere(r)), and related agents. Int Immunopharmacol 3/13–14: 1699–1714

    Google Scholar 

  11. Friedland D, Cohen J, Miller R et al. (1999) A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2. Semin Oncol 26 (Suppl): 19

    CAS  Google Scholar 

  12. Gravis G, Bladou F, Salem N et al. (2003) Weekly administration of docetaxel for symptomatic metastatic hormone-refractory prostate carcinoma. Cancer 98 /8: 1627–1634

    Google Scholar 

  13. Haas N, Roth B, Garay C et al. (2001) Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer. Urology 58/1 59–64

    Google Scholar 

  14. Haldar S, Basu A, Croce C (1997) Bcl-2 is the guardian of microtubule integrity. Cancer Res 57/2: 229–233

    Google Scholar 

  15. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC (2001) Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year John Hopkins experience. Urol Clin North Am 28/: 555–565

  16. Hudes GR, Greenberg R, Krigel RL et al. (1992) Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J Clin Oncol 10/11: 1754–1761

    Google Scholar 

  17. Hudes GR, Nathan F, Khater C et al. (1997) Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol 15/9: 3156–3163

    Google Scholar 

  18. Jakate AS, Einhaus CM, DeAnglis AP, Retzinger GS, Desai PB (2003) Preparation, characterization and preliminary application of fibrinogen-coated olive oil droplets for the targeted delivery of docetaxel to solid malignancies. Cancer Res 63/21: 7314–7320

    Google Scholar 

  19. Kantoff PW, Halabi S, Conaway M et al. (1999) Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 17/8: 2506–2513

    Google Scholar 

  20. Kelly WK, Curley T, Slovin S et al. (2001) Paclitaxel, estramustin phosphate and carboplatin in patients with advanced prostate cancer. J Clin Oncol 19/1: 44–53

    Google Scholar 

  21. Khan MA, Carducci MA, Partin AW (2003) The evolving role of docetaxel in the management of androgen independent prostate cancer. J Urol 170/5: 1709–1716

    Google Scholar 

  22. Koletsky AJ, Guerra ML, Kronish L (2003) Phase II study of vinorelbine and low-dose docetaxel in chemotherapy-naive patients with hormone-refractory prostate cancer. Cancer J 9/4: 286–292

    Google Scholar 

  23. Kuzel TM, Kies MS, Wu N et al. (2002) Phase I trial of oral estramustine and 3-hr infusional paclitaxel for the treatment of hormone-refractory prostate cancer. Cancer Invest 20/5–6: 634–643

    Google Scholar 

  24. Logothetis CJ (2002) Docetaxel in the integrated management of prostate cancer. Current applications and future promise. Oncology 16 (6 Suppl 6): 63–72

    Google Scholar 

  25. Markman M (2003) Management of toxicities associated with the administration of taxanes. Expert Opin Drug Saf 2/2: 141–146

    Google Scholar 

  26. Meluch AA, Greco FA, Morrissey LH et al. (2003) Weekly paclitaxel, estramustin phosphate and oral etoposide in the treatment of hormone-refractory prostate carcinoma. Cancer 98/10: 2192–2198

    Google Scholar 

  27. Miller K, Steiner U, Machtens S, Backhaus B, Siegsmund M, Johannsen M, Wülfing C (2003) Combination chemotherapy with weekly docetaxel and intermittent estramustine in patients with hormone-refractory prostate cancer (HRPC): A multicenter phase II study. Proc ASCO 22: 1660

    Google Scholar 

  28. Oh WK, Halabi S, Kelly WK, Werner C, Godley PA, Vogelzang NJ, Small EJ (2003) A phase II study of estramustine, docetaxel and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma. Cancer and Leukemia Group B 99813. Cancer 98 /12: 2592–2598

    Google Scholar 

  29. Oudard S, Banu E, Voog E et al. (2003) Results of a phase II randomized trial of docetaxel, estramustine and prednisone – two schedules – versus mitoxantrone and prednisone in patients with hormone-refractory prostate cancer. Eur Urol 2 (Suppl 1): 189 /Abstract 746

    Google Scholar 

  30. Pavithran K, Doval DC (2002) Nail changes due to docetaxel. Br J Dermatol 146/4: 709–710

    Google Scholar 

  31. Petrioli R, Pozzessere D, Messinese S et al. (2003) Weekly low-dose docetaxel in advanced hormone-resistant prostate cancer patients previously exposed to chemotherapy. Oncology 64/4: 300–305

    Google Scholar 

  32. Petrylak DP (1999) chemotherapy for advanced hormone refractory prostate cancer. Urology 54 (Suppl 6A): 30–35

    Article  CAS  PubMed  Google Scholar 

  33. Petrylak DP, Macarthur RB, O’Connor J et al. (1999) Phase I trial of docetaxel with estramustine in androgen-independant prostate cancer. J Clin Oncol 17/3: 958–967

    Google Scholar 

  34. Petrylak DP, Shelton GB, England-Owen C et al. (2000) Response and preliminary survival results of a phase II study of docetaxel (D) and estramustine (E) in patients with androgen-independant prostate cancer (AIPCA). Proc Am Soc Clin Oncol 19: 334a

    Google Scholar 

  35. Picus J, Schultz M (1999) Docetaxel (taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin Oncol 26 (Suppl): 14

    CAS  Google Scholar 

  36. Pruitt-Scott DE, Ryan CW, Stadler WM, Vogelzang NJ (2002) Exisulind (EXI) plus docetaxel (DOC) for hormone-refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 21: 161b

    Google Scholar 

  37. Pienta KJ, Redman B, Hussain M et al. (1994) Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol 12/10: 2005–2012

    Google Scholar 

  38. Ratan HL, Gescher A, Steward WP, Mellon JK (2003) ErbB receptors: possible therapeutic targets in prostate cancer? BJU Int 92/9: 890–895

    Google Scholar 

  39. Read WL, Mortimer JE, Picus J (2002) Severe interstitial pneumonitis associated with docetaxel administration. Cancer 94/3: 847–853

    Google Scholar 

  40. Reese DM, Small EJ, Magrane G et al. (2001) HER2 protein expression and gene amplification in adrogen-independant prostate cancer. Am J Clin Pathol 116/2: 234–239

    Google Scholar 

  41. Roth BJ, Yeap BY, Wilding G et al. (1993) Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group. Cancer 72/8: 2457–2460

    Google Scholar 

  42. Sampath D, Discafani CM, lo ganzo F et al. (2003) MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivo. Mol Cancer Ther 2/9: 873–884

  43. Savarese DM, Halabi S, Hars V et al. for the Cancer and Leukemia Group B (2001) Phase II study of docetaxel, estramustine and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. J Clin Oncol 19/9: 2509–2516

    Google Scholar 

  44. Scher H, Steineck G, Kelly WK (1995) Hormone-refractory (D3) prostate cancer: Redefining the concept. Urology 46/2: 142–148

    Google Scholar 

  45. Schnorr D (1999) Palliativtherapie des hämatogen metastasierten Prostatakarzinoms. In: Hinkelbein W, Miller K, Wiegel Th (Hrsg) Prostatakarzinom—urologische und strahlentherapeutische Aspekte. Springer, Berlin Heidelberg New York Tokio, S 89–104

  46. Scholz MC, Guess B, Barrios F, Strum S, Leibowitz R (2001) Low-dose, single-agent weekly docetaxel (taxotere) is effective and well tolerated in elderly men with prostate cancer. Proc Am Soc Clin Oncol 20: 173b

    Google Scholar 

  47. Shionoya M, Jimbo T, Kitagawa M, Soga T, Tohgo A (2003) DJ-927, a novel oral taxane, overcomes P-glycoprotein-mediated multidrug resistance in vitro and in vivo. Cancer Sci 94/5: 459–466

    Google Scholar 

  48. Sinibaldi VJ, Carducci MA, Moore-Cooper S et al. (2002) Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen-independant prostate carcinoma. Cancer 94/5: 1457–1465

    Google Scholar 

  49. Sitki Copur M, Ledakis P, Lynch J et al. (2001) Weekly docetaxel and estramustine in patients with hormone-refractory prostate cancer. Semin Oncol 28/4 (Suppl 15): 16–21

    Google Scholar 

  50. Small EJ, Bok R, Reese DM, Sudilovsky D, Frohlich M (2001) Docetaxel, estramustine plus trastuzumab in patients with metastatic androgen-independant prostate cancer. Sem Oncol 28 (4 Suppl 15): 71–76

    Article  CAS  Google Scholar 

  51. Smith DC, Esper P, Strawderman M et al. (1999) Phase II trial of oral estramustine, oral etoposide and intravenous paclitaxel in hormone-refractory prostate cancer. J Clin Oncol 17/6: 1664–1671

    Google Scholar 

  52. Smith DC, Chay CH, Dunn RL et al. (2003) Phase II trial of paclitaxel, estramustine, etoposide and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma. Cancer 98/2: 269–276

    Google Scholar 

  53. Solit DB, Morris M, Slovin S et al. (2003) Clinical experience with intravenous estramustine phosphate, paclitaxel and carboplatin in patients with castrate, metastatic prostate adenocarcinoma. Cancer 98/9: 1842–1848

    Google Scholar 

  54. Sollott SJ, Cheng L, Pauly RR et al. (1995) Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat. J Clin Invest 95/4: 1869–1876

    Google Scholar 

  55. Song YW, Kim HA, Baek HJ, Lee EB, Chung ES, Hong KM (1998) Paclitaxel reduces anti ds-DNA antibody titer and BUN, prolonging survival in murine lupus. Int J Immunopharmacol 20/11: 669–677

    Google Scholar 

  56. Tannock IF, Osoba D, Stockler MR et al. (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomised trial with palliative end points. J Clin Oncol 14/6: 1756–1764

    Google Scholar 

  57. Trivedi C, Redman B, Flaherty LE et al. (2000) Weekly 1-hour infusion of paclitaxel. Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma. Cancer 89/2: 431–436

    Google Scholar 

  58. Tsavaris N, Kosmas C, Vadiaka M et al. (2002) Immune changes in patients with advanced breast cancer undergoing chamotherapy with taxanes. Br J Cancer 87/1: 21–27

    Google Scholar 

  59. Vaishampayan U, Parchment RE, Jasti BR, Hussain M (1999) Taxanes: an overview of the pharmacokinetics and pharmacodynamics. Urology 54 (Suppl 6A): 22–29

    Article  CAS  PubMed  Google Scholar 

  60. Van Feldhuizen PJ, Reed G, Aggarwal A et al. (2003) Docetaxel and ketoconazole in advanced hormone-refractory prostate carcinoma. A phase I and pharmacokinetic study. Cancer 98/9: 1855–1862

    Google Scholar 

  61. Vaughn DJ, Brown A, Harker WG (2003) Phase II evaluation of weekly paclitaxel (P) and estramustine phosphate (EMP) in androgen-independant prostate cancer. Proc ASCO 22: Abstract 1615

    Google Scholar 

  62. Wirth MP, Nippgen J (2003) Chemotherapie beim hormonrefraktären Prostatakarzinom. Urologe A 42/11: 1453–1460

    Google Scholar 

Download references

Interessenkonflikt:

Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen.

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Urologie, Humboldt-Universität, Berlin

    M. Johannsen, K. Wilke, D. Schnorr & S. A. Loening

  2. Klinik und Poliklinik für Urologie, Campus Charité-Mitte, Charité-Universitätsmedizin Berlin, Schumannstr. 20–21, 10117, Berlin

    M. Johannsen

Authors
  1. M. Johannsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Wilke
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. Schnorr
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. A. Loening
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Johannsen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Johannsen, M., Wilke, K., Schnorr, D. et al. Taxane in der Chemotherapie des hormonrefraktären Prostatakarzinoms. Urologe [A] 43, 160–167 (2004). https://doi.org/10.1007/s00120-004-0528-3

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-004-0528-3

Schlüsselwörter

Keywords

Search

Navigation